Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
12 participants
INTERVENTIONAL
2018-06-01
2024-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real-life Management and Therapeutic Outcome of Patients With Chronic Rhinitis and Chronic Urticaria in Thailand
NCT02000648
A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions
NCT00600847
Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine
NCT05107115
Treatment Options for Chronic Urticaria
NCT06816784
An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)
NCT01916967
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Desloratadine
Oral desloratadine 20 mg/day (antihistamine) for 4 weeks
Desloratadine
Desloratadine 20 mg/day
Desloratadine plus cilostazol and dipyridamole
Oral desloratadine 20 mg/day (antihistamine) in conjunction with cilostazol 150 mg/day and dipyridamole 50 mg/day (antiplatelets) for 4 weeks
Desloratadine plus cilostazol and dipyridamole
Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day
Desloratadine
Desloratadine 20 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Desloratadine plus cilostazol and dipyridamole
Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day
Desloratadine
Desloratadine 20 mg/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
D-dimer levels over 500 ng/ml
Not respond to a conventional dose of antihistamine
Exclusion Criteria
Have bleeding tendency
Have concurrent severe medical illnesses
\-
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Assoc. Prof. Jettanong Klaewsongkram, MD.
Assoc. Prof. Jettanong Klaewsongkram, MD.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jettanong Klaewsongkram, MD
Role: PRINCIPAL_INVESTIGATOR
Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine, Chulalongkorn University
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Chula-ARC 001/18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.